A Pilot Study of AVD plus Brentuximab Vedotin to Treat Stage II-IV HIV-Associated Hodgkin Lymphoma

Full Title

A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma (AMC 085)


ABVD chemotherapy includes the drugs doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine and is the most commonly used standard chemotherapy for Hodgkin lymphoma. However, bleomycin is a weak drug against this cancer and can cause lung problems. In this study, researchers are evaluating the safety and effectiveness of combining a powerful drug called brentuximab vedotin (also called SGN-35) with doxorubicin, vinblastine, and dacarbazine (AVD) in patients with previously untreated stage II-IV Hodgkin lymphoma who also have HIV infection.

Brentuximab has two parts: one (an antibody) that attaches to a protein on the surface of cancer cells (including Hodgkin lymphoma) called CD30, and another (an anticancer drug called monomethyl auristatin E) that kills the cancer. Brentuximab is already approved for the treatment of certain patients with relapsed or refractory Hodgkin lymphoma, but prior clinical trials did not include patients with HIV.

This study is being conducted through the AIDS Malignancy Clinical Trials Consortium, a National Cancer Institute-sponsored group that conducts clinical studies of new treatments for patients with cancer who have HIV.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have previously untreated stage II-IV CD30-positive Hodgkin lymphoma.
  • Patients must have HIV infection.
  • Patients’ CD4 counts should be 50 cells/µl or more.
  • This study is open to patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Ariela Noy at 212-639-7423.